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ABSTRACT
Trans-lPtCl(N,N-dimethylamine)(isopropylamne)] is a novel trans-platinum compound that shows
,.’ytotoxic activity in several cisplatin resistant cell lines. The aim of this paper was to analyse, bv means of
molecular cell biology techniques and total reflection X-ray fluorescence (TXRF), the cytotoxic Activi.ty. the
induction of apoptosis, the cellular uptake and the DNA binding of trans-[PtCl(N,:V-
dimethylamine)(isopropylamine)] in the cisplatin resistant cell line A2780cisR. The results show that this drug
is more cytotoxic and induces a higher amount of apoptotic cells than cisplatin in A2780:isR cells. However,
the intracellular accumulation and extent of binding to DNA of trans[PtCl(N, N-
dimethylamine)(isopropylamine)] is lower than that of cis-DDP. Moreover, trans-lPtCl(N,N..
dimethylamine)(isopropylamhae)] is partially inactivated by intracellular levels of glutathione. The resull
suggest that circumvention of ciplatin resistance by trans-lPtCl(N, N-diaethylarnine)(iepropylrni.ne)] ir
A2780cisR cells might be related with the ability of this drug to induce
INTRODUCTION
Cisplatin [cis-diammmedichloroplatinum (II), cis-DDP] is one of the most widely used
drugs in the treatment of cancer. It shows remarkable activity alone or in combination with
other drugs in the treatment of several tumors, including those of the lung, ovary, testes and
bladder [1, 2]. The success of cis-DDP as an antiturnor drug has been attributed to different
factors, including penetration of the cellular membrane, accumulation in the tumor cell. and
efficiency in coordinating with chromosomal DNA [3, 4]. The extent ofDNA lesions induced by
cis-DDP in the cell nuclei and the cell killing potential of the drug is believed to depend on the
cellular level of reactive platinum species and the persistence of platinum within the cells [5, 6].
Despite the success of cis-DDP against certain types of cancer, the patients treated with the drug
suffer from severe side effects including nephrotoxicity, nausea and vomiting, myelosuppression
and ototoxicity [2, 3]. Moreover, quite often tumors become resistant to cisplatin [7]. The cis-
DDP resistance may take place at various levels, including cellular accumulation, interaction with
glutathione (GSH) and/or metallothioneins, DNA repair and defective apoptotic program [8].
Although transplatin or trans-DDP (the stereoisomer of cisplatin) is clinically inactive,
several classes of trans-platinum complexes show antitumor activity and some ofthem are able
to circumvent cisplatin resistance [9]. Trans-[PtCl2(N,N-dimethylamine)(isopropylamine)]
(Figure 1) is a novel trans-platinum(II) complex with mixed aliphatic amine ligands which show
cytotoxic activity in tumor cell lines sensitive and resistant to cisplatin [ 10]. Moreover, trans.
[PtC12(N,N-dimethylamine)(isopropylamine)] induces tumor cell death through apoptosis [ 11 ].
The A2780cisR human ovarian tumor cell line may be considered a model to study cisplatin-
resistance because it exhibits acquired resistance to cis-DDP from a combination of decreased
uptake, enhanced DNA repair/tolerance and elevated GSH levels [ 1.2, 13 ]. The results reported in
this paper indicate that trans-[PtCl2(N,N-dimethylamine)(isopropylamine)] is able to overcome
cisplatin-resistance in A2780cisR cells through apoptoss induction. Trans-[PtClz(N,N-
dimethylamine)(isopropylamine)] induces a higher percentage of apoptotic cells than cisoDDP
both in A2780 and A2780cisR cell lines. However, the intracellular accurnulation and extent of
binding to DNA of trans-[PtClz(N,N-dimethylamine)(isopropylanine)] ir A2780cisR cells is
lower than that of cis-DDP. Interestingly, the cytotoxic activity and the binding to DNA of
trans-[PtC12(N, N-dirnethylamine)0sopropylarnine)] in A2780eP eell increases by previous cel!
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treatment with the GSH inactivator, L-buthionine sulfoximine (L-BSO) suggesting that the drug
is partially inactivated by GSH.
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Figure 1. Structures and molecular weights of trans-
[PtC12(N,N-dimethylamine)(isopropylamine)], cis-DDP
and trans-DDP.
MATERIALS AND METHODS
Biological reagents and drugs. 100-mm culture and micro well plates were obtained from NUNCLON
(Roskilde, Denmark): MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) was purchased from
Sigma. FCS was supplied by GIBCO-BRL. cis-DDP and trans-DDP were purchased from Sigma. Trans-
[PtC12(N,N-dimethylamine)(isopropylamine)] was synthesized as previously reported 10]. Stock solutions of
the compounds (1 mg/nfl) inDMEM medium (Dulbecco’s modified Eagles Medium) were freshly prepared
before use.
Cell Lines and Culture Conditions. The pair ofhuman ovarian tumor cell lines (A2780/A2780cisR) were
cultured inDMEM medium (Dulbecco’s modified Eagles Medium) supplemented with 10% FCS (foetal calf
serum) together with 2 mM glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin at 37C in an
atmosphere of95% of air and 5% CO.
Drugs Cytotoxicity. Cell death was evaluated by using a system based on the tetrazolium compound MTT
which is reduced by living cells to yield a soluble formazan product that can be assayed colorimetrically 14].
E.xnentially growing A2780 and A2780cisR cells [15] were plated in 96-well sterile plates, at a densi.ty of
10 cells/well in 100 Ixl of medium, and were incubated for 3-4 hours. Stock solutions of the compounds
dissolved inDMEM were added to the wells at final concentrations from 0 to 300 lxM, in a volume of
100d/well. After twenty-four hours of incubation, 50 lxl ofa freshly diluted MTT solution (1/5 in culture
medium) was added to a final concentration of 1 mg/ml into each well and the plate was further incubated for 5
hours. Cell survival was evaluated by measuring the absorbance at 520 nrn, using a Whittaker Microplate reader
2001. IC50 values (drug concentrations that induces 50% of cell death) were calculated from curves consmacted
by plotting cell survival (%) versus compound concentration (tM). All experimems were made in
quadruplicate.
Quantification ofapoptosis by annexin Vbinding andflow cytometry. A2780 and A2780cisR cells were
exposed to 2xlC50 of the platinum drugs for 24 hours. Attached and detached cells were recovered,, mixed and
resuspended in annexin V binding buffer (PharMingen). 2.5 tl ofpropidium iodide (PI, Sigma) and I tg/ml
of annexin V-fluorescein isothiocyanate (PharMingen) were added, and the cells were left at room temperature
before flow cytometric analysis in a FACScalibur Beckton-Dickinson apparatus. The percentage of apoptotic
cells induced by each platinum drug (percentage ofannexin V-positive/Pl negative cells) was calculated from
the annexinV/PI scattergrams.
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Measurements ofplatinum accumulation. Cultures plates containing exponentially growing A2780cisR cells in
10 ml ofDMEM medium (cell density 2 x 10 cells/ml) were exposed to 50 lxM of the platinum drugs
dissolved inDMEM medium for 1, 3 or 24 hours. Cells were washed with ice-cold PBS, scraped and
resuspended in 700 [xl of lysis buffer containing 20 mM Tris.HC1, pH 7.5, 2 mM EDTA and 0.4% Triton X-
100. incubated at 4C for 15 min and centrifuged at 12.000 rpm for 15 min in a centrifuge. Afterwards,
supernatants were treated for 3 hours at 37C with 20 txg/ml ofproteinase K (Boehringer). The platinum content
in the samples was determined by TXRF (total. reflection X-ray fluorescence). Experiments were camed out in
triplicate.
Determination ofplatinum binding to DNA in vivo. Culture plates containing exponentially growing
A2780cisR cells in 10 ml ofDMEM medium (cell density 2 x 10 cells/ml) were exposed to 50 laM of the
platinum drugs dissolved in DMEM. The plates were incubated for 1, 3 or 24 hours under the conditions
described above. Following drug incubation, culture medium was removed from the plates and the cell plates
were washed with PBS. Subsequently, the cells were lysed with 700 lxl of a buffer solution containing 150
mM Tris.HCl pH 8.0, 100 mM EDTA and 100 mM NaCI, incubated for 15 minutes at 4C and centrifuged at
12.000 rpm for 15 min in a microfuge. Supernatants were treated for 3 hours at 37C with 20 lxg/ml of
proteinase K (Boehringer). Afterwards, supematants were incubated for 16 hours at 37C with 100tg/ml of
RNase A (Boehringer). Finally, DNA was extracted with a volume ofphenol-chloroform-isoamyl alcohol (50 +
49 + 1), precipitated with 2.5 volumes of cold ethanol and 0.1 volumes of 3 M sodium acetate, washed with
75% of ethanol, dried and resuspended in 1 ml of water. TheDNA content in each sample was measured by
UV spectrophotometry at 260 nm in a Shimadzu UV-240 spectrophotometer and platinum bound to DNA was
determined by TXRF. Experiments were carried out in triplicate.
Total reflection X-rayfluorescence measurements. The analysis by TXRF was performed using a Seifert Extra-
II spectrometer (Seifert, Ahrensburg, Germany). TXRF determinations were carried out according to a procedure
previously reported 16]. Briefly, a 100 lal sample of either cell supernatants or cellularDNAs from the cell
cultures was introduced in a test tube of 2 ml. This solution was standardised with 100 ng/ml ofVanadium
[Merck (Darmstadt,Germany) ICP Vanadium standard solution]. Afterwards, the sample was introduced into a
high-purity nitrogen flow concentrator at a temperature of70C until the vohtme was reduced five times. An
aliquot of 5 tl was then taken, deposited on a previously clean quartz-made reflector and dried on a ceramic
plate at a temperature of 50C. The entire process was done in a laminate flow chamber (Model A-100). The
samples were analysed following the X-ray Molybdenum line under working conditions of 50 kV and 20 mA
with a live-time of 1000 s and a dead time of 35%. Spectra were recorded between 0 and 20 keV. The
following 15 elements were simultaneously analysed: P, S, K, Ca, V, Fe, Cu, Zn, As, Br, Rb, Sr, Ni. Mn and
Pt, in order to obtain a correct deconvolution of profiles associated with the general spectrum. The Pt line was
used for Pt quantification. The analytical sensitivity of the TXRF measurements was 0.3 to 22.4 ng Pt in a
solution volume of 100 tl, with repeatability between 2 and 8% (n 3).
lntracellular GSH content, lntracellular GSH levels were determined, in A2780 and A2780cisR cells growing
as specified for the Cytotoxicity tests. Approximately 5 xl05 cells/ml were seeded into P100 plates, and, after
overnight incubation, cells were washed twice with ice-cold PBS. Cellular GSH was then extracted using 2 ml
of ice-cold 0.6% sulfosalicilic acid followed by a 10 min incubation at 4C. Total GSH content in the extract
was then determined according to the method of Griffiths[ 18]. Protein quantification was carded out after
solubilization in 2 ml of sodium hydroxide 1M using the Lowry assay [19]. The GSH levels were expressed as
nmol/mg protein.
Depletion ofGSH levels in A2780cisR cells. A2780cisR cells were pre-exposed for 24 hours to 50 pM of L-
buthionine sulfoximine (L-BSO). This resulted in an approximately 80% reduction in GSH levels 17]. The
growth inhibitory effect of the platimm compounds after 24 hours ofdrug exposure was then determined using
the MTT method.
Statistical Analysis. Where appropriate, statistical significance was tested using a two-tailed Student’s test.
RESULTS AND DISCUSSION
Cytotoxic activity.
We have tested the cytotoxic activity of trans-[PtCl2(N.N-
dimethylamine)(isopropylamine)], cis- and trans-DDP against A2780 and A2780cisR cells after
a treatment period of 24 hours. Table 1 shows that in A2780 cells the IC50 value of trans-
[PtCl2(N,N-dimethylamine)(isopropylamine)] was similar to that of cis-DDP (3.7 tM and 3.6
tM, respectively). In contrast, the tC50 value of trans-DDP was 30-fold higher (110 tM) than
those of trans-[PtCl:(N, N-dimethylamine)(isopropylamine)] and cis-DDP. Interestingly, trans-
[PtCl(N,N-dimethylamine)(isopropylamine)] had a cytotoxic activity 2o6-times and more than
13.6-times higher than cis-DDP and trans-DDP in the cisplatin resistant tumor cell line
A2780cisR (ICs0 values of 22 tM, 58 btM and > 300 [xM, respectively).
Because GSH is involved in intracellular detoxification of metal drugs [20], we have also
evaluated the effect _of GSH on the cytotoxic activity of trans-[PtCl(N,N-
dimethylamine)(isopropylamine)], cis-DDP and trans-DDP by using L-BSO (L-buthlonine
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sulfoximine) to decrease the levels ofGSH in A2780cisR cellsprior to drug-treatment. Our
determinations ofGSH intracellular content indicated that the A2780cisR cell line possesses
about 6-times higher glutathione levels than its parental A2780 cell line (GSH levels: nmol/mg
protein, A2780 8.5 __. 025; A2780cisR 50 .+_ 0.8; p<0.01). These data are in agreement
with previous data reported in the literature and indicate that the A2780cis R cell line has high
intrinsic levels ofGSH [ 13]. Interestingly, Table 1 shows that while potentiation of cvtotoxicity
in A2780cis R cells was only slight for cis-DDP it was significantly laigh for the two {rans
complexes trans-[PtCl(N,N-dimethylamine)(lsopropylamine)] and trans-DDP (p<0.01).
Altogether these results iiadicate that trans-[PtClz(N,N-dirnethylamine)(isopropylamine)] is able
to circumvent cisplatin resistance in A2780cisR cells. In addition, the cytotoxcity data obtained
in the presence or absence of preoexposure to L-BSO also suggest that as previously found for
other trans-platinum conplexes [22, 23], trans-[PtC12(N,N-dimethvlamine ) (isopopvlamine)]
may be also more susceptle to inactivation by reaction with GSH {han cIs-DDP.
Table I. IC50 mean values obtained for trans-[PtClz(N,N-dinethylamine)(isopropylamine)], cis-DDP and
trans-DDP against A2780 and A2780cisR cell lines for a drug-treatment period of24 hours. (+ L-BSO)
indicates that the cells were preincubated for 24 hours with 50 txM ofL-buthionine sulfoximine in order to
d=e__plete cellular glutathion levels. SD=stan_dd deviation..............., ........................................
Ovarian carcinoma cell system A2780/A2780cisR
A2780 A2780cisR A2780cisR (+LBSO)
trans-[PtCl(dma)Opa)]* 3.7 +/- 0.1 22 +/- 3 5.0 +/- 0.3
c/s-DDP 3.6 +/- 0.4 58 +/- 4 50 _
2
trans-DDP 110 +/- 8 >300 144 +/- 10
Apoptosis induction.
After a 24 hours treatment period with equitoxic doses (2xlC50) of cis-DDP, trans-DDP
and trans-[PtCl(N,N-dimethylamine)(isopropylamine)], there was a greater cell detachment
from the culture plate surface in A2780 cells compared with A2780cisR cells, as revealed by
phase contrast microscopy (data not showaa). Cell detachment has been previously reported as an
indication of apoptosis induction [ 11, 12]. Both detached and attached cells were mixed and
assayed by a flow cytometric annexin V binding assay [24]. Annexin V binds phosphatidyl serine
residues that are asymmetrically distributed to the inner plasma membrane but move to the outer
plasma membrane early in apoptosis. Figure 2 shows that treatment with trans-[PtCl(N,N-
dimethylamine)(isopropylamine)] induced a higher increase in the annexin V-positive/PI
negative cell population (right bottom quadrant) than. treatment with cis-DDP or trans-DDP
both in A2780 (Fig. 2: panels B, C and D, respectively) and A2780cis cells (Fig 2. panels F, G
and H, respectively) The annexin V-positive/PI negative cell population constitutes the fraction
of apoptotic cells [24].
Table II shows the percentage of apoptotic cells induced by the platinum compounds in
A2780 and A2780cisR cells as calculated from the scattergrams of Figure 2. As can be observed
in Table II, all the platinum drugs induced a higher percentage of apoptotic cells in the A2780
line than in the A2780cisR line. Thus, trans-[PtCl(N,N-dimethylamine)(isopropylamine)] killed
most ofA2780 cells through apoptosis (91.97 %). Moreover, the percentage of apoptotic
A2780 cells induced by trans-[PtC12(N,N-dimethylamine)(isopropylamine)] was two-times and
three-times higher than those induced by cs-DDP (45.20%) and trans-DDP (29.26%),
respectively. In addition, trans-[PtClz(NiN-dimethylamine)(isopropylamine)]also induced a
significant percentage of apoptotic cells in the A2780eisR line (58.38%). This percentage was
1.7-times and 5.0 times higher than those induced by cis-DDP (34.24 %) and trans-DDP (10.59
%), respectively. Altogether, the results indicate that the lower the dose of drug needed to kill
the cells the higher the percentage of apoptosis induction [25]. Thus, trans-[PtCl:(N,N-
dimethylamine)(isopropylamine)] has a higher ability to induce apoptosis than both cis-DDP and
trans-DDP in the pair of cell lines A2780/A2780cisR. Inversely, the data also suggest that the
higher the doe of drug needed to kill the cells the higher the percentage of induction of necrosis
[25]. Thu, it is interesting to note that trans-DDP induced high percentages of necrosis both n
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.A2780 (46,08%) grad A27g0ciR cells (60,62%).. "l’his finding might be related with the
bi.okgica m.eft!icacy of tr’am,’..DDP [41[.
A C D
E F G H
Figt.s! Z, Quami:ficafio ef apoN:osis after 24 hers exsure to 2xIC0 ofe
p.la:ti:mm:, d:r.,gs i. A27g0 and A2780cisR ceils. Representative nen VI
fluo:rc;.:c;.c<: sca:ttcr.g’ams ;;aowi.:g A2Tg0 cclt;: com:rol (A), trans-[NCl=(N,N-
methyta:m:ae)(i::apopy!.amine)] .reatme::t (.{), cis,;DDP treanent (C) and trans-
DDP tr(’:atmeN (D); .ad A2780cisR. cells: cotrol. (F), trans-[NCl=(N,N-
dhtmtDlaU.::xe:)(iseprmg.ami::e)] treatme,t (G), cis,DDP treatmem (I:: and ans-
TaMe i.I Perce..,,tag.::. of aive, a,popteti.= at;d necmtic c.,::.lls it the ovarian ccinoma cell wem
A27gO/A278(}cisR. a:7::" 24 hours of m::ammnt wi trans-[NClz(NN
dimethylamie)(iopmpy.a:m.me:,)], ct>DDP :n.d #",:ms.,.DDP. The data were takenfo the annen
.Tg A2780cR
A.ve A.!,:e@: N: r’t.; Alive Apoptotic Ntic
Crtr! 99,,’7{ 0 0,,22 9965 0.01 0.34
tll,.a,pa 6 9 91,97 1,11 7, 6 58,38 34.46
.l :) 45.20 3"7 51 22.85 34.24 42.91
t’ans..DlP 24.66 29.26 .1608 28,79 10.59 60.62
Total mtracllu...ar platinum levels {:mud m A2780eisR cells aRer exposure to 50 gM of
th.e platinum drug R,r 7,., 3 and 24 ho..rs are shown i: Figure 3. R may obseed that cellular
uptake ofcs4)DP, teo,;;-DDP arid tn:,::s.]PtCt(N;N.dhnethylamine)(isopropylamine)] increased
a.: a fUnctio, of time { .A27g0ciaR cls.. At :draft p{:riods of drug treatment cellular levels of
tnms-,[PtC12(N;]-dimethylamme) (isopmpyamke) were lower than. th.ose of cis-DDP d
tromd.)DP. Tlm, the: mtracellular l.evel; of cis..DDP, trans-DDP md trans-[PtCl2(,N-
dimethylami:m)(isopropylamme}] m .. A278 ( "’,: 0.13, 0.12d 0.10 p,mol/2x10 cells
after 1 hour of mcba.tion a.ad progre:::ive,y flmreased to reach respectively 0.41 0.35 and 0,12
0 btmol/2xl0
e; c,.tI,, a{ter 3 hc,a of i:m::ubatio:. and 0.42, 0.37 m..d 0.30 mol/2xl
g cells aRer 24
hours ef incubatio.. Thus, a:(:r 24 h.oua of incubaI:ioa ofA2780cisR cells with a 50M
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concentration of cis-DDP, trans-DDP and trans-[PtCl_(N,N-dimethylamine) (isopropylamine)],
the percentage of intracellular platinum in A2780cisR cells relative to the platinum input was
82%, 74% and 60%, respectively. These data indicate that intracellular accumulation of trans-
[PtCl(N,N-dimethylamine) (isopropylamine)] in A2780cisR cells is lower than that of both cis-
DDP and trans-DDP. We think that the lower cellular uptake of trans-[PtCl2(N.N-
dimethylamine) (isopropylamine)] relative to cis-DDP and trans-DDP might be related to its
larger rnolecular size.
Figure 3. Cellular uptake of 50 tM of trans-[PtCl:(N,N-
dimethylamine)(isopropylamine)] (*), cis-DDP and
trans-DDP () in A2780cisR cells. The results are
expressed as means _+ SD (n=3).
Pt accumulation in A2780cisR cells
0,5
0
0 5 10 15 20 25
time (hours)
tdmaipa ----I- cis-DDP ---A trans-DDP
Figure 4. DNA binding kinetics of 50 txM of trans-
[PtCl(N,N-dimethylamine)(isopropylamine)] (,), cis-DDP
) and trans-DDP () in A2780cisR cells The results
are expressed as means __. SD (n=3).
Pt-DNA binding in A2780cisR cells
800
0 5 10 15 20 25
time (hours) -----
tdmaipa cis-DDP ---A-- trans-DDP
Platinum-DNA binding in A2780cisR cells.
Platinum-DNA binding levels in A2780cisR cells incubated with the platinum drugs (50
txM) for 1, 3 and 24 hours are show:n in Figure 4. The binding of the drugs began to be
quantifiable only after 1 hour of incubation. The DNA binding kinetics of cis-DDP, trans-DDP
and trans-[PtC12(N,N-dimethylamine) (isopropylamine)] showed that the binding of these drugs
to DNA increased as function of time in A2780cisR cells. The higher level ofDNA binding was
shown by cis-DDP. In contrast, the levels ofDNA binding of trans-DDP were lower than those
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of cis-DDP and trans-[PtC12(N,N-dimethylarnine)(isopropylamine)] at all the periods of
incubation tested. The binding of cis-DDP, trans-[PtCl2(N,N-dimethylamine)(isopropylamine)]
and trans-DDP to DNA was respectively 180, 40 and 20 nmol/g DNA after 1 hour of
incubation and progressively increased to reach respectively 810, 590 and 480 nmol/g DNA
after 24 hours of incubation.
We also quantified the levels of platinum binding to DNA when the A2780cisR cells
were pre-exposed to L-BSO before treatment with the platinum drugs. Figure 5 shows that
under these conditions the level of DNA binding shown by cis-DDP, trans-[PtCl2(N,N-
dimethylamine)(isopropylamine)] and trans-DDP increased relative to that found in
A2780cisR cells not pre-exposed to L-BSO. Interestingly, the higher increase in DNA binding
was shown by trans-[PtC12(N,N-dimethylamine)(isopropylamine)]. Thus, the kinetics ofDNA
binding of trans-[PtCl(N,N-dimethylamine)(isopropylamine)] was very similar to that of cis-
DDP in A2780cisR cells pre-exposed to L-BSO. These results support the cytotoxicity data
reported above and suggests that trans-[PtCl2(N,N-dimethylamine)(isopropylamine)] is
significantly more affected in its reaction with DNA by cellular levels ofGSH than cs-DDP.
Figure 5. DNA binding kinetics of 50 txM of trans-
[PtCl2(N,N-dimethylamine)(isopropylamine)] (), cis-DDP
and transoDDP (L) in A2780cisR cells pre-exposed
for 24 hours to 50 laM ofL-BSO.The restdts are expressed
as means +/- SD (n=3).
Pt-DNA binding In A2780ctsR cells(+L-BSO)
800
600 .......................................................-.
400
200
0
0 5 10 15 20 25
time (hours)
----.- tdrnaipa -----cis-DDP --
trans-DDP
The results described in this paper show that trans-[PtC12(N,N-
dime.thylamine)(isopropylamine)] is able to circumvent cisplatin resistance in A2780cisR
ovarian tumor cells. Thus, trans-[PtCl:(N,N-dimethylamine)(isopropylamine)] e.xhibits greater
cytotoxicity against A2780cisR cells than both cis-DDP (approximately 2.6-times as potent)
and trans-DDP (more than 13.6-times as potent). Moreover, trans-[PtCl_(N.N-
dimethylamine)(isopropylamine)] is a better inductor of apoptosis in A2780cis R cells than
both cis-DDP (1.7-times as better) and trans-DDP (5.5-times as better). These results are in
agreement with previously reported data, which showed that trans-[PtCl2(N,N-dimethylamine)
(isopropylamine)] is also able to circumvent cisplatin resistance and induces apoptosis in Pam
212-ras murine keratinocytes [ 10, 11 ].
It has been reported that the A2780cisR human ovarian tumor cell line e.xhibits acquired
resistance to cis-DDP from a combination of decreased uptake, enhanced DNA
repair/tolerance and elevated GSH levels [12, 13]. The aim of the present study was to
investigate whether the cellular uptake, the reaction with GSH and the level ot platinum
binding to DNA of trans-[PtC12(N,N-dimethylamine)(isopropylamine)] may help to understand
the mechamsm(s) by which this drug overcomes cisplatin resistance. Our results show that both
the cellular uptake and the bnding of trans-[PtClz(N,N-dimethylamine)(isopropylamine)] to
DNA in A2780cisR cells are lower th-an those of cis-DDP. In addition, trans-[PtCl2(N.N-
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dimethylamine)(isopropylamine)] seems to be inactivated by reaction with GSH at a higher
extent than cisDDP. In fact, either the cytotoxic activity or the amount of binding to DNA
of trans-[PtCl.(N, N-dimethylamine)(isopropylamine)] in A2780cisR cells significantly
increased when intracellular levels ofGSH were depleted with L-BSO before treatment with the
platirum drug. In contrast, both the cytotoxic activity and the amount of cis-DDP binding to
.OqA are not significtly altered when GSH levels in A2780cisR cells are depleted with L-BSO
prior to cis-l)DP treatment. Therefore, the intracellular accumulation, the reaction with GSH
md fle level of platinum binding to DNA are factors, which cannot explain the circumvention
of clsplatin re,sistance shown by trans-[PtCl2(N,N-dimethylamine) (isopropylamine)] in
A2780cisR cells.
Emerging evidence suggest that an important number of cases of cisplatin resistance
might be the result of the inability of cis-DDP to induce cell death through apoptosis in
particular cell lines [8, 25]. We think that circumvention of ciplatin resistance by trans-
[]?tCl(N,N-dimethylamine) (isopropylamine)] might be directly related with the ability of this
drug to induce apoptosis in A2780cisR cells. It is generally accepted that DNA damage and
subsequent induction of apoptosis may be the primary cytotoxic mechanism of platinum drugs
[2 6]. Although the level of binding to DNA of trans-[PtCl(N,N-
dimethylamine)(isopropylamine)] in A2780cisR cells is lower than that of cis-DDP it can not
be ruled mt the possibility that a specific type ofDNA adduct might be involved in the
induction of apoptosis by trans-[PtCl(N,N-dimethylamine)(isopropylamine)]. In fact, we have
previously repoted that trans-[PtCl2(N,N-dimethylamine)(isopropylamine)] forms a higher
amount ofDNA interstrand cross-links than cis-DDP in linear pBR322 plasmid [27]. Although
the irter,trand crossqinks represent a minor proportion of the total lesions produced by cis-
DDP on DNA, they have often implicated with cytotoxicity [28]. Alternatively, trans-
[PtC12(N,N-dimethylamine)(isopropylamine)] might induce apoptosis in A2780cisR cells
through interaction with other targets (i.e., proteins, phospholipids, cytoskeleton etc.) and
ubscquent cellular damage. Further research is warranted to test these two hypotheses.
AC.:NOWLEDGEMENTS
I’lfis woIk was supported by grants SAF00-0029 and BIO-99/1133.We also thanks the European Cost
[)2(/001/00 and D20/0003/00 Actions. An institutional grant from Fundaci6n Ram6n Areces is also
ackowledged. We thank Johnson Matthey plc. for their generous gift ofKPtC14.
[.$i[iERENCES
1. Rosenberg B. Cancer, 55, 2303-2316, 1985.
2. O’Dwyer P.J., Stevenson J.P. and Johnson SW. In Csplatin. Chemistry and biochemistry ofa
leading anticancer drug, Lippert, B., Ed.; Wiley-VCH, Basel, Switzerland, 1999; pp 31-72.
3 Kelland L.R. (’ritRev Oncol/Hematol, 15, 191-219. 1993.
4. JamJeson E.R and Lippard S.J. Chem Rev, 99, 2467-2498, 1999.
5. Gately D.P. and Howell S.B. Brit J Cancer, 67, 1171-1176, 1993.
6. Di BlasJ P., BernareggJ A., Beggiolin G., Piazzoni L., Menta E. and Formento M.L. Anticancer Res,
18, 3113.-3118, 1998.
7. Andrews P.A. and Howell SB. Cancer Cells, 2, 35-43, 1990.
8 P6rcz I.P. EurJ (.’ancer, 34,1535--1544, 1998.
9. P6rez J.M., Fuertes M.A., Alonso C. and Navarro-Ranninger C. Crit Rev Oncol/Hematol, 35, 109-
120, 2O0O.
10. Montcro EoI., Diaz S., Gonz’ilez-Vadillo A.M., P6rez J.M.. Alonso C. and Navarro-Ranninger C. JMed
Chem, 42, 4264-4268, 1999.
11. P6rez, J.M., Montero, E.I., (nzilez, A.M., Alvarez-Vald6s, A., Alonso, C. and Navarro-Ranninger, C.
Jlnorg Biochem, 77, 37-42, 1999.
12. Kelland L.R., Barnard C.F.J., Mellish K.J., Jones M., Godard P.M., Valenti M., Bryant A., Murrer
B.A. and. Harrap K.R. Cancer Res, 54, 5618-5622, 1994.
13. Kelland L.R. and Barnard C.D.J. Drugs Fur. 23, 1062-1065, 1999.
14. Alley M.C. and. Boyd M.R. Cancer Res, 48, 589-601, 1998.
15. Kellhnd L.R., Abel G., McKeage M.J., Jones M., Goddard P.M., Valenti M., Murrer B.A. and Harrap
K.R. Cancer Res, 53, 2581-2586, 1993.
16. Fcrnndez-Ruiz R., Tomero JoD., Gonzfilez, V.M. and Alonso C. Analyst, 124, 583-585, 1999.
17. Kelland L.I., Bamard C.F.J., Mellish K.J., Jones M., Goddard P.M., Valenti M., Bryant A., Murrer
B.A. and Harrap KoR. Cancer Res., 54, 5618-5622, 1994.
18. Gtffiths O.W. Ahal Biochem, 106, 207.o211, 1980.
19. lowy O..H. Rosebrough N.J., Farr AoL. and Randall R.J. J Biol Chem, 193, 265-275, 1951.
36Metal BasedDrugs ;":L 8, Nr. 1, 2001
20.
21.
22.
23.
24.
27.
28.
Pendyala L., Creaven P.J., P6rez R., Zdanowicz J.R and Raghavan D. Cancer Chemother t"ha’macol,
36, 271-278, 1995.
Mistry P., Kelland L.R., Abel G., Sidhar S. and Harrap K.R. BritJ Cancer 64 215-.22(, 19) 1o
Andrews P.A., Murphy M.P. and Howell S.B. Cancer Res, 45, 6250-6253, 1985.
Goddard P., Valenti M. and Kelland L.R. Antieaneer Res, 14,, 1065-1070, 1994
Van Engeland M., Nieland L.J.W., Ramaekers F.C.S., Schutte B. and Reutenlingspergcr
Cytometry, 31, 1-9, 1998.
Gonzilez V.M., Fuertes M.A., Alonso C. and P6rez, J.M. Mol PharmacoL 2001
Eastman A. In Cisplatin. Chemisto and biochemistry ofa leading anticancer drug Lippet,.
Wiley-VCH, Basel, Switzerland, 1999; pp 111-134.
P6rez J.M., Montero E.I., Gonzilez A.M., Solans X., Font--Bardia M., Fuees MAo
Navarro-Ranninger C. JAted Chem, 43, 2411.-2418, 2000.
I.,eng M. and Brabec V. InDNA adducts: Identification and biological significance. Hemmi;,.ki
Dipple A, Shuker DEG, Kadlubar FF, Segerb/ck d and Bartsch HEds. IARC ScienlificPpubiic.io5
No 125, Lyon, International Agency for Research on Cmacer, 1994, pp 339-348.
37